Publication
Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.
Authors not recorded
Clin Cancer Res2013PMID 23812671PMC3777641stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMelanomacivic_curation1.00
- drugNutlin-3civic_curation1.00
- drugPLX4720civic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF V600Ecivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23812671
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF V600E1 | ||||||||
| Nutlin-3 + PLX4720Combination | Melanoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID97Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 melanoma cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly m… (full text at CIViC) PMID 23812671 · Ji et al., 2013 · Open in CIViC | civic |